OpenResearchAlpha

bioRxiv · 11 Nov 2026

A modified Arrestin1 Slows Retinal Degeneration Across Genetically Distinct Mouse Models of Inherited Retinal Disease

Ruining Peng, Kristin Ates-Hicks, Seok Hong Min, Stephanie Wohlgemuth, Astra Dinculescu, W. Clay Smith

0
Citations
no database records one yet
0
Citations in 2026
so far
–
Leading author's h-index
no author has a profile yet
0
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Inherited retinal diseases (IRDs) are a genetically heterogeneous group of disorders caused by mutations in more than 340 genes, limiting the applicability of gene-targeted therapies and creating the need for broader treatment strategies. Photoreceptor dysfunction is a hallmark of IRDs and often results in disrupted retinal metabolic homeostasis, as photoreceptors have exceptionally high metabolic demands and provide metabolic resources to surrounding retinal cells. Consequently, enhancing retinal metabolism has emerged as a promising gene-agnostic strategy for treating IRDs. We previously developed a modified arrestin1 (ArrGG) that relieves arrestin1-mediated inhibition of the glycolytic enzyme enolase1, thereby increasing glycolytic output and slowing retinal degeneration in the RhoP23H/+ mouse model. Here, we investigated the therapeutic potential of ArrGG as a gene-agnostic approach targeting endogenous metabolic enzyme activity across genetically distinct models of IRD. Using two complementary photoreceptor-enriched transcriptomic analyses, we found no widespread, reproducible transcriptional changes following ArrGG treatment. These findings support our hypothesis that ArrGG modulates photoreceptor metabolism without inducing substantial transcriptional remodeling. The therapeutic efficacy of ArrGG was evaluated in three IRD mouse models representing rapid rod degeneration (rd10), cone degeneration (GC1KO), and RPE-associated retinal degeneration (rd6). ArrGG treatment was associated with preserved retinal function and slowed structural degeneration across all three models. Together, these findings support the potential of modulating endogenous metabolic enzyme activity to preserve photoreceptors across genetically distinct IRD models. This work suggests that ArrGG could be a promising gene-agnostic metabolic therapy for slowing retinal degeneration and preserving visual function in inherited retinal diseases.

Neuroscience

What the data shows

  • No database records a citation yet, as is usual for a paper this new.

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (6)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (0)

What it cites, from open citation data, with Crossref's record of each.

No references in the open citation data yet.
A modified Arrestin1 Slows Retinal Degeneration Across Genetically Distinct Mouse Models of Inherited Retinal Disease - QAI OpenResearch